1. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study. Issue 6 (21st February 2021) Authors: Barritt, A. Sidney; Watkins, Stephanie; Gitlin, Norman; Klein, Samuel; Lok, Anna S.; Loomba, Rohit; Schoen, Cheryl; Reddy, K. Rajender; Trinh, Huy Ngoc; Mospan, Andrea R.; Vos, Miriam B.; Weiss, L. Michael; Cusi, Kenneth; Neuschwander‐Tetri, Brent A.; Sanyal, Arun J. Journal: Hepatology communications Issue: Volume 5:Issue 6(2021) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗